A progressive movement disorder in a patient with multiple myeloma treated with anti-BCMA CAR-T cells that might have been related to on-target activity in the brain supports prospective neurologic monitoring after BCMA-targeting therapies.
- Oliver Van Oekelen
- Adolfo Aleman
- Samir Parekh